Specialty Select
Specialty Pharmacy Spend You Can Actually Control
Specialty drugs are the fastest-growing line item in your benefits budget—and most PBMs profit from keeping that complexity hidden. NeosRx Specialty Select gives you transparent access, AI-powered routing, and clinical management built around your members, not our margins.
Unbiased Pharmacy Routing for Lower Net Cost
Most PBMs own the specialty pharmacies they route members to. That means every routing decision is shaped by their revenue—not your costs, and not your members’ needs.
NeosRx has no financial ties to any specialty pharmacy. That independence is what makes lowest-net-cost routing possible—and credible.
Built for Sponsor Savings
Because NeosRx does not own pharmacies, we can direct claims to the best option for your plan and your members.
Unbiased
No financial ties to any specialty pharmacy—zero conflict of interest in routing.
Wide Network
Full accredited network of 277 specialty NPI locations and 26 partners—critical for rare disease and limited distribution drugs.
Transparent
100% acquisition cost transparency. Plan sponsors see exactly what NeosRx pays and every dollar saved.
Flexibility with AI-Powered Routing
- Real-time waste detection
- Clinical intervention alerts
- Lowest-cost routing engine
- Proactive adherence monitoring
- PA optimization
- Split-fill and cycle control
Where Clinical Management Moves the Needle Most
Specialty spend isn’t monolithic. The biggest savings come from targeting the highest-cost, highest-complexity drug categories with the right clinical intervention at the right moment. Here’s where Specialty Select focuses.
Drug/Condition | Role | Unmanaged Cost | Estimated Savings |
|---|---|---|---|
Hemlibra (emicizumab) Hemophilia A with / without inhibitors | Waste prevention—weight-based dose calculator, 4-vial-size elimination protocol | Avg $176K / 6 months unmanaged | 27% cost reduction |
MS Disease-Modifying Therapies Ocrevus, Kesimpta, Tysabri, Tecfidera | Clinical intervention—pharmacist-led monitoring, adherence management, site-of-care optimization | $80K–$120K+ per patient per year | Up to $156K avoided per patient |
Oral oncology Ibrance, Imbruvica, Revlimid—breast cancer, CLL, multiple myeloma | Adherence + split-fill—day-7 tolerance check, PA initiation, PDC/MPR tracking | $9,850–$16,000+ per month; 80% non-adherent | Avoids $10K+ per wasted fill |
Specialty infusion Ocrevus, Rituxan, Entyvio—MS, IBD, RA, oncology | Site of care coordination—redirects hospital-billed drugs to office or home infusion | Hospital outpatient: 3–5× markup vs. office / home | 33–52% / $16K–$37K per patient per year |
GLP-1 management Ozempic, Wegovy, Zepbound, Mounjaro | Utilization management—step therapy, diagnosis validation, lifestyle program linkage at 90-day mark | $900–$1,300+ per month; only 14% persist 3 years | 10–25% PMPM reduction |
Member
Get StartedTake Control of Your
Healthcare Costs
Hands-On Clinical Support, Aligned Pharmacy Management.
Work with a partner who builds a PBM with you and for you.